/CADL
CADL Stock - Candel Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$5.57+0.54%
+$0.03 (+0.54%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.58
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+169.3%upside
Target: $15.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CADL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.51 – $5.63
TARGET (TP)$15.00
STOP LOSS$5.12
RISK/REWARD1:21.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.92
52W High$13.68
52W Low$4.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $125,000 | $125,000 | $125,000 |
| Gross Profit | $-990,000 | $-23,980,000 | $125,000 | $-14,469,000 | $125,000 |
| Gross Margin | N/A | N/A | 100.0% | -11575.2% | 100.0% |
| Operating Income | $-33,371,000 | $-38,391,000 | $-34,722,000 | $-25,726,000 | $-13,810,000 |
| Net Income | $-55,177,000 | $-37,939,000 | $-18,794,000 | $-36,124,000 | $-17,680,000 |
| Net Margin | N/A | N/A | -15035.2% | -28899.2% | -14144.0% |
| EPS | $-1.74 | $-1.31 | $-0.10 | $-1.26 | $-1.18 |
Company Overview
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$17
Average Target
↑ 197.5% Upside
Now
$7
Low
$17
Average
$25
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 28th 2025 | Stephens | Initiation | Overweight | $15 |
| September 3rd 2025 | BofA Securities | Downgrade | Neutral | $7 |
| June 30th 2025 | H.C. Wainwright | Resumed | Buy | $23 |
| February 20th 2025 | Citigroup | Initiation | Buy | $25 |
| February 19th 2025 | Canaccord Genuity | Initiation | Buy | $20 |
| February 7th 2025 | BofA Securities | Initiation | Buy | $15 |
| December 2nd 2022 | H.C. Wainwright | Initiation | Buy | $11 |
Earnings History & Surprises
CADLBeat Rate
47%
Last 15 quarters
Avg Surprise
+1.0%
EPS vs Estimate
Beats / Misses
7/8
Last 12 quarters
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q1 24
-137.5%
$-0.38vs$-0.16
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
-73.9%
$-0.40vs$-0.23
Q2 25
+154.2%
$0.13vs$-0.24
Q3 25
+47.1%
$-0.09vs$-0.17
Q4 25
-23.5%
$-0.21vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.24 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.17 | $-0.21 | -23.5% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.17 | $-0.09 | +47.1% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.24 | $0.13 | +154.2% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.23 | $-0.40 | -73.9% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | — | $-0.33 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-0.74 | — | — |
Q2 2024 | May 14, 2024 | — | $-0.28 | — | — |
Q1 2024 | Mar 28, 2024 | $-0.16 | $-0.38 | -137.5% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.19 | $-0.29 | -52.6% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.23 | $-0.33 | -43.5% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.35 | $-0.30 | +14.3% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.16 | $-0.18 | -12.5% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.53 | $-0.30 | +43.4% | ✓ BEAT |
Q3 2022 | Aug 5, 2022 | $-0.54 | $-0.14 | +74.1% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.49 | $-0.03 | +93.9% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-0.32 | $0.05 | +115.6% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-0.27 | $-0.34 | -25.9% | ✗ MISS |
Q3 2021 | Sep 8, 2021 | $-0.12 | $-0.31 | -158.3% | ✗ MISS |
Latest News
Stephens & Co. Reiterates Overweight on Candel Therapeutics, Maintains $15 Price Target
📈 PositiveBenzinga•Dec 8, 2025, 02:03 PM
Candel Therapeutics To Present Data About Solid Tumors At Society For Immunotherapy Of Cancer In Maryland
📈 PositiveBenzinga•Nov 4, 2025, 02:03 PM
Stephens & Co. Initiates Coverage On Candel Therapeutics with Overweight Rating, Announces Price Target of $15
📈 PositiveBenzinga•Oct 28, 2025, 10:12 AM
LifeSci Capital Initiates Coverage On Candel Therapeutics with Outperform Rating, Announces Price Target of $16
📈 PositiveBenzinga•Oct 21, 2025, 02:52 PM
Candel Therapeutics Secures $130M Loan Facility To Fund Phase 3 Trial And Advance Cancer Pipeline
📈 PositiveBenzinga•Oct 14, 2025, 12:14 PM
Candel Therapeutics Reports Glioblastoma Trial Data As Study Reveals CAN-3110 Triggers Immune-Driven Tumor Remodeling In The Journal "Science Translational Medicine"
📈 PositiveBenzinga•Oct 14, 2025, 12:13 PM
Candel Therapeutics To Present Insights From enLIGHTEN Discovery Platform, And Additional Data From CAN-2409 Program In NSCLC, At SITC Annual Meeting
➖ NeutralBenzinga•Oct 3, 2025, 01:11 PM
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 04:22 PM
Candel Therapeutics Announces CAN-2409 Significantly Improves Disease-Free Survival In Prostate Cancer, Showing Benefit Across Radiation Modalities In Phase 3 Trial
📈 PositiveBenzinga•Sep 29, 2025, 12:20 PM
Candel Therapeutics To Present At ASTRO 2025 Sept. 28
➖ NeutralBenzinga•Sep 17, 2025, 12:06 PM
Candel Therapeutics shares are trading lower after B of A Securities downgraded Candel Therapeutics to Neutral and cut its price target from $13 to $7.
📉 NegativeBenzinga•Sep 3, 2025, 04:11 PM
B of A Securities Downgrades Candel Therapeutics to Neutral, Lowers Price Target to $7
📉 NegativeBenzinga•Sep 3, 2025, 03:54 PM
Candel gains after FDA RMT designation for lead asset
📈 PositiveSeeking Alpha•May 28, 2025, 02:27 PM
Frequently Asked Questions about CADL
What is CADL's current stock price?
Candel Therapeutics, Inc. (CADL) is currently trading at $5.57 per share. The stock has moved +0.54% today.
What is the analyst price target for CADL?
The average analyst price target for CADL is $15.00, based on 1 analyst.
What sector is Candel Therapeutics, Inc. in?
Candel Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CADL's market cap?
Candel Therapeutics, Inc. has a market capitalization of $0.31 billion, making it a small-cap company.
Does CADL pay dividends?
No, Candel Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
CABA
Cabaletta Bio, Inc.
$2.39
Mkt Cap: $0.2B
CAPR
Capricor Therapeutics, Inc.
$27.81
Mkt Cap: $1.3B
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$11.74
Mkt Cap: $0.3B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
GNLX
Genelux Corporation
$4.20
Mkt Cap: $0.2B
IMMP
Immutep Limited
$2.63
Mkt Cap: $0.4B
KYTX
Kyverna Therapeutics, Inc.
$7.19
Mkt Cap: $0.3B
MREO
Mereo BioPharma Group plc
$2.00
Mkt Cap: $0.3B
PRQR
ProQR Therapeutics N.V.
$2.21
Mkt Cap: $0.2B
Explore stocks similar to CADL for comparison